No abstract

Objective The purpose of this study is to investigate the acute toxicity, progression-free survival and overall survival in patients of nasopharyngeal carcinoma (NPC) treated with or without calcium folinate. Methods 1. Total of 422 patients with nasopharyngeal carcinoma were recruited from July 1, 2002 to December 31, 2014, including chemotherapy regimen of PF and CPF regimen. 2. The imformation of acute toxicities, recurrence and metastasis, and survival time were collected. 3. Data processing and analysis by Graphpad prism 6 software. Results 1. The overall survival of the Group CPF as compared to the Group PF at 3, 5,10 and 12 years were 97.42% vs. 91.24%，94.61% vs. 87.44%，88.74% vs. 81.98% and 88.74% vs. 78.57%, respectively. The OS of Group CPF got higher than that of Group PF (P=0.0269). 2. The overall survival rate of CPF group was significantly higher than that of group PF in clinical stage I-III, the overall survival was 90.83% vs. 82.12%，respectively（P=0.0348）. 3. The local control rate of the Group CPF as compared to the Group PF were 97.06% vs. 73.91% in stage T4 (P=0.0133). 4. No significant difference in other indicators between the two groups in hematological toxicity, except for Grade 3 neutropenia. 5. The incident of side effects of digestive system, such as nausea and vomiting, the Group CPF as compared to the Group PF were 45.06% vs. 67.31% and 33.95% vs. 46.15%，respectively（P=0.0000，P=0.0036）. Conclusions 1. Calcium folinate can significantly prolong the overall survival rate of patients with nasopharyngeal carcinoma, especially in Stage I-III（90.83%）. 2. Calcium folinate can significantly improve the local control rate in patients with T4（97.06%）. 3. It shows obvious protective effects on digestive system（33.95%）